The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats

被引：13
作者：
Rahman, Asadur [1 ]
Sherajee, Shamshad J. [1 ]
Rafiq, Kazi [1 ]
Kobara, Hideki [2 ]
Masaki, Tsutomu [2 ]
Nakano, Daisuke [1 ]
Morikawa, Takashi [3 ]
Konishi, Yoshio [3 ]
Imanishi, Masahito [2 ]
Nishiyama, Akira [1 ]
机构：
[1] Kagawa Univ, Fac Med, Dept Pharmacol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan
[2] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Takamatsu, Kagawa, Japan
[3] Osaka Gen Hosp, Div Hypertens & Nephrol, Osaka, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2020年 / 142卷 / 03期
关键词：
LCZ696; Proteinuria; Diabetic kidney disease (DKD); HEART-FAILURE; SACUBITRIL/VALSARTAN; FIBROSIS;
D O I：
10.1016/j.jphs.2019.09.014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
We examined the effects of the angiotensin receptor-neprilysin inhibitor LCZ696 on overt proteinuria and renal injury in type 2 diabetic Otsuka-Long- Evans-Tokushima-Fatty (OLETF) rats. Aged OLETF rats were also treated with either valsartan or valsartan plus hydralazine for comparison. LCZ696 caused greater attenuation of the progression of proteinuria than either valsartan alone or valsartan combined with hydralazine. Reduced glomerular injury and tubulointerstitial fibrosis were also observed in LCZ696-treated rats. Moreover, LCZ696 prevented increases in blood urea nitrogen (BUN) and creatinine levels. These data suggest that LCZ696 elicits a reno-protective effect against type 2 diabetes with overt proteinuria. (C) 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
引用
收藏
页码：124 / 126
页数：3
相关论文
共 14 条
  • [1] Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
    Coresh, Josef
    Heerspink, Hiddoj L.
    Sang, Yingying
    Matsushita, Kunihiro
    Arnlov, Johan
    Astor, Brad C.
    Black, Corti
    Brunskill, Nigel J.
    Carrero, Juan-Jesus
    Feldman, Harold, I
    Fox, Caroline S.
    Inker, Lesley A.
    Ishani, Areef
    Ito, Sadayoshi
    Jassal, Simerjot
    Konta, Tsuneo
    Polkinghorne, Kevan
    Romundstad, Solfrid
    Solbu, Marit D.
    Stempniewicz, Nikita
    Stengel, Benedicte
    Tonelli, Marcello
    Umesawa, Mitsumasa
    Waikar, Sushruts
    Wen, Chi-Pang
    Wetzels, Jack F. M.
    Woodward, Mark
    Grams, Morgan E.
    Kovesdy, Csaba P.
    Levey, Andrew S.
    Gansevoort, Ron T.
    Hallan, Stein
    Shalev, Varda
    Chalmers, John
    Arima, Hisatomi
    Perkovic, Vlado
    Levin, Adeera
    Djurdjev, Ognjenka
    Tang, Mila
    Nally, Joseph
    Navaneethan, Sankar
    Schold, Jesse
    Weldegiorgis, Misghina
    Herrington, William
    Smith, Margaret
    Feldman, Harold
    Hsu, Yenchih
    Fox, Caroline
    Hwang, Shih-Jen
    Chang, Alex R.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (02) : 115 - 127
  • [2] Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy
    Diez, Javier
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (02) : 167 - 176
  • [3] Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
    Heerspink, Hiddoj L.
    Greene, Tom
    Tighiouart, Hocine
    Gansevoort, Ron T.
    Coresh, Josef
    Simon, Andrew L.
    Chan, Tak Mao
    Hou, Fan Fan
    Lewis, Julia B.
    Locatelli, Francesco
    Praga, Manuel
    Schena, Francesco Paolo
    Levey, Andrew S.
    Inker, Lesley A.
    Schrier, Robert W.
    Estacio, Raymond O.
    Perkovic, Vlado
    Parving, Hans-Henrik
    Carlo, Manno
    Zucchelli, Pietro
    Brenner, Barry M.
    Barret, Brendan
    Kamper, Anne-Lise
    Strandgaard, Svend
    Rodby, Roger A.
    Rohde, Richard D.
    Lewis, Edmund
    Wanner, Christoph
    von Eynatten, Maximilian
    Katafuchi, Ritsuko
    de Jong, Paul E.
    van Essen, G. G.
    Xie, Di
    Perrone, Ronald D.
    Abebe, Kaleab Z.
    Li, Philip
    Leung, C. B.
    Szeto, C. C.
    Chow, K. M.
    Del Vecchio, Lucia
    Andrulli, Simeone
    Pozzi, Claudio
    Maes, Bart
    Dwyer, Jamie
    Lachin, John M.
    Goicoechea, Marian
    Verde, Eduardo
    Caravaca, Fernando
    Gutierrez, Eduardo
    Sevillano, Angel
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (02) : 128 - 139
  • [4] Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
    Ito, Sadayoshi
    Satoh, Minoru
    Tamaki, Yuko
    Gotou, Hiromi
    Charney, Alan
    Okino, Naoko
    Akahori, Mizuki
    Zhang, Jack
    [J]. HYPERTENSION RESEARCH, 2015, 38 (04) : 269 - 275
  • [5] Jing WH, 2017, AM J TRANSL RES, V9, P5473
  • [6] Neprilysin inhibition in chronic kidney disease
    Judge, Parminder
    Haynes, Richard
    Landray, Martin J.
    Baigent, Colin
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (05) : 738 - 743
  • [7] Proteinuria in Diabetes: Bystander or Pathway to Cardiorenal Disease?
    Karalliedde, Janaka
    Viberti, Giancarlo
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (12): : 2020 - 2027
  • [8] Cardiovascular Disease and Diabetic Kidney Disease
    Maqbool, Muhammad
    Cooper, Marke.
    Jandeleit-Dahm, Karin A. M.
    [J]. SEMINARS IN NEPHROLOGY, 2018, 38 (03) : 217 - 232
  • [9] Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
    McMurray, John J. V.
    Packer, Milton
    Desai, Akshay S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 993 - 1004
  • [10] Clinical predictive factors in diabetic kidney disease progression
    Radcliffe, Nicholas J.
    Seah, Jas-Mine
    Clarke, Michele
    MacIsaac, Richard J.
    Jerums, George
    Ekinci, Elif I.
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (01) : 6 - 18
12